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Background: Systemic lupus erythematous (SLE) is a multi-system
autoimmune disease which has a relapsing and remitting course.
Patients with lupus nephritis (LN) are at risk of relapse and hence long
term follow up and disease monitoring are of particular importance.
Anti-C1q antibodies (C1Q Ab) are observed in 30-60% of patients with
SLE. It has been postulated that the presence of C1Q Ab can predict a
flare of LN. Here we undertook a prospective follow up of patients after
having a C1Q Ab measurement to determine whether the result
predicted a flare of LN.
Methods: SLE patients attending an Inner-City Lupus Center, were
involved in the study. All fulfilled the 2012 SLICC criteria for SLE. A
point-in-time measurement of C1Q Ab was made using an ELISA kit
(Orgentec Diagnostika GmbH). A positive test defined by the
manufacturer is a level above 10 U/ml. Medical records of patients
were reviewed over the following 1 year to identify LN flares. A renal
flare was defined as a doubling of the protein creatinine ratio with a
subsequent decision to escalate immunosuppressive therapy. Chi
Squared tests were used to assess statistical significance. 9 patients
who were being treated for a flare of LN at the time of C1Q Ab were
excluded from the analysis.
Results: 116 lupus patients were included in the study. Of those, 52
had biopsy proven LN (45%). Positive C1Q ab was more common in
patients with a history of biopsy proven LN (n¼17, 32.7%) compared
to those with non-renal SLE (n¼10, 15.6%),(p¼ 0.03). Renal flares
tended to be more common in C1q ab positive LN patients (n¼ 4,
26.7%) compared to those without C1q ab (n¼2, 7.14%). (p¼0.782).
Of the 64 patients with non-renal SLE, 1 (10%) C1Q Ab positive patient
subsequently developed LN compared with 1 (1.85%) C1Q Ab
negative patient (p¼0.173).There was no correlation between the
level of C1Q Ab and the rate of LN flares. Having a positive dsDNA
antibody level at the time of sampling also did not appear to predict a
flare.
Conclusion: C1Q Ab has a known correlation with LN, however its
ability to predict flares has been less well characterised. Our
prospective analysis shows that although the C1Q Ab positive patients
were more likely to have a flare of LN in the following year, there was
not a statistically significant difference between the C1Q Ab positive
and negative groups. In addition, only a relatively small proportion of
C1Q Ab positive patients went on to have a flare (20%). Our data
therefore does not support the use of C1Q Ab as a predicting factor for
a subsequent flare of LN.
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Background: Cardiovascular disease is the leading cause of mortality
for patients with lupus. Understanding increased cardiovascular risk
(CVR) in autoimmune diseases could improve CVR management in
patients. The objective of a patient-focused event was to explore
patient opinions about CVR and potential treatment options. A
secondary objective was to learn about lupus patient experiences
with diet including their opinion on considering diet as a therapeutic.
Methods: We hosted a patient event promoted through social media,
relevant charities, hospitals and research groups. 13 patients with
lupus and/or Sjögren’s syndrome attended and were asked about CVR
using a questionnaire and round table discussion with researchers,
clinicians and dietitians. In addition, a 15-question diet-based online
survey was made publicly available for 3 weeks promoted through the
same methods as the patient event.
Results: Sixty percent of patients were aware of the increased CVR
associated with autoimmune rheumatic disease and 60% stated that
their doctor had spoken to them about CVR. 73% thought that it was
important for them to be aware of this increased CVR. When asked
about medication to reduce CVR; no patients wanted to take a statin
(lipid-lowering drug), however, 70% of patients would take statins if
advised by their doctor. Conversely, respondents were more positive
about using diet or taking a dietary supplement to reduce CVR; 71%
would change their diet and 57% would take a supplement either on
their own accord or on advice from health professionals. Some
patients had already made changes to their diet to reduce their CVR,
including reducing fat and increasing fruit and vegetable consumption.
All attendees were prepared to participate in a clinical study using diet
modification strategies, having vascular scans to assess atherosclero-
sis and provide blood samples for CVR research in lupus. An online
survey was used to further assess lupus patient opinion on modifying
their diet depending on their CVR. 284 responses were received over 3
weeks. Patients reported there was a lack of clinical counselling
regarding diet with only 24% of patients stating that their doctor had
spoken to them about diet. Despite this, 100% of patients stated that
they would change their diet if they knew it would help their symptoms
and 83% would take part in a diet-based clinical trial, supporting the
results from the face-to-face patient event. Text analysis of patient
research suggestions identified an interest in using diet to manage
fatigue and disease activity.
Conclusion: This multidisciplinary event and online survey success-
fully gathered patient information regarding CVR and diet. The
opinions and comments provided evidence that patients support
further research in cardiovascular studies, a demand for increased
CVR and dietary clinical counselling and a preference to changing their
diet, whilst avoiding medication, to reduce their CVR.
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Background: Vitamin D deficiency is more prevalent in patients with
systemic lupus eythematosus (SLE) as a result of sun avoidance. The
potential negative impact of vitamin D deficiency on the disease
activity of SLE has been shown in a number of studies. The expression
of the interferon signature genes in SLE correlates positively with
disease activity, and these genes are thought to mediate the clinical
manifestations of the disease. The aim of this study was to establish
whether a relationship exists between serum 25-hydroxyvitamin D
level and the interferon signature gene expression in whole blood of
SLE patients.
Methods: Informed consent was obtained from 92 SLE patients who
were over the age of 18 and who fulfilled the SLICC classification
criteria for SLE. The patients were interviewed and blood tests
including full blood count, renal profile, calcium, 25-hydroxyvitamin
D, complement 3 (C3), complement 4 (C4) and anti-double standed
DNA (anti-dsDNA) titre were carried out. SLE disease activity was
measured by SLE disease activity index-2K (SLEDAI-2K). RNA
extraction was performed from whole blood. QuantiGene Plex
technology was used to measure the expression of 12 interferon
signature genes in the extracted RNA. The study was approved by the
University Research Ethics Committee.
Results: 92.4% of the cohort studied were female. 58.7% were
receiving vitamin D3 supplementation at a mean dose of 1031IU daily.
27.2% had vitamin D insufficiency (25-hydroxyvitamin D 21-29ng/ml)
and 15.2% were vitamin D deficient (25-hydroxyvitamin D<20ng/ml).
Mean serum 25-hydroxyvitamin D was 30.75ng/ml (standard deviation
9.53 ng/ml). Median SLEDAI-2K was 4 (range 0-12). Serum 25-
hydroxyvitamin D had a significant negative correlation with body
mass index (BMI) (R¼-0.258, p¼0.006) but there was no significant
negative correlation with SLEDAI-2K or with the expression of the
interferon signature genes. The expression of most interferon
signatures genes measured (IFI35, OAS1, MX1, IFITM1, STAT2,
IFIT3, IFIT1, STAT1, SOCS1) had a significant positive correlation
with SLEDAI-2K.
Conclusion: This study did not show a significant relationship
between serum vitamin D level and disease activity. In keeping with
this, there was no significant negative correlation between serum 25-
hydroxyvitamin D and interferon signature gene expression. Further
prospective studies and randomised controlled trials are required to
study this relationship in greater depth.
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SPONDYLARTHROPATHIES (INCLUDING
PSORIATIC ARTHRITIS)
EP37 LONG-TERM EVALUATION OF SECUKINUMAB 150 MG
IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY
EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
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Background: Evaluation of long-term efficacy and safety for treat-
ments for ankylosing spondylitis (AS) is important. Secukinumab, a
fully human monoclonal antibody that directly inhibits interleukin-17A,
has shown significant and sustained improvement in the signs and
symptoms of AS through 3 years in the MEASURE 2 study
(NCT01649375). We report the 5-year end-of-study results of
subcutaneous (SC) secukinumab 150 mg in MEASURE 2.
Methods: AS patients (N¼ 219) were randomised to receive SC
secukinumab 150 mg, 75 mg or placebo at baseline, Weeks 1, 2 and 3
and every 4 weeks from Week 4. At Week 16, placebo-treated patients
were re-randomised to receive secukinumab 150/75 mg. Efficacy
results are reported for patients initially randomised to secukinumab
150 mg and those who switched from placebo to secukinumab 150 mg
at Week 16 (N¼ 106). An optional dose escalation from secukinumab
75 mg to 150 mg was initiated beginning Week 140. Outcome
measures at Week 260 included ASAS20/40, BASDAI50, BASMI,
BASFI, SF-36 PCS[JB1] and ASAS partial remission. Analyses
stratified by TNF inhibitor (TNFi) status (TNFi-naive and TNFi
inadequate response [IR]) were performed. Safety analysis included
all patients who received 1 dose of secukinumab. Results are
reported as observed.
Results: The retention rate to Week 260 was 77% (82/106) for
secukinumab 150 mg. Sustained efficacy was observed with secuki-
numab 150 mg across all endpoints through 5 years. Improvements
were maintained regardless of prior exposure to TNFi therapy with
greater responses in TNFi-naive patients. A total of 49 patients on
secukinumab 75 mg (46.7%) escalated dose to 150 mg after Week
140; efficacy responses improved in patients whose dose was
escalated. Over the entire study period, the mean exposure (SD) to
secukinumab was 1459.1  597.8 days. Exposure-adjusted incidence
rates (per 100 patient-years) with any secukinumab dose for selected
adverse events were: Candida infections (1.0), Crohn’s disease (0.5),
major adverse cardiovascular events (0.7), uveitis (0.5), and malignant/
unspecified tumours (0.5).
Conclusion: Conclusion: Secukinumab 150 mg provided sustained
improvement in the signs, symptoms, and physical function in patients
with AS through 5 years of treatment. The safety profile of
secukinumab remained consistent with previous reports.
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Background: Enthesitis can be a debilitating extra-articular spondy-
loarthritis manifestation that causes considerable pain and reduced
quality of life. We evaluated the effect of secukinumab on axial and
peripheral enthesitis in ankylosing spondylitis (AS) patients with
baseline enthesitis (BLE) across all MASES sites (N¼13), axial
MASES sites (N¼11; 13 MASES minus Achilles tendons [AT] [AxS]),
peripheral sites (N¼ 6; AT þ lateral condyles of humerus/femur [PS])
and the AT (N¼ 2) at Weeks 16 and 52.
Methods: This post-hoc analysis pooled data across four AS studies
(MEASURE 1-4) from patients originally randomised to secukinumab
150 mg (approved AS dose), 300 mg (MEASURE 3 only) or placebo
with BLE (MASES >0). Evaluations included mean change from
baseline in MASES score, complete resolution (CR; MASES¼0) and
improvement from baseline in MASES score 5 counts. Mixed-effect
model repeat measurement analysis was performed on change from
baseline in MASES score and non-responder imputation for resolution
of enthesitis at Week 16; data are reported as observed at Week 52.
Results: 355 (70.4%), 58 (76.3%) and 280 (72%) patients had BLE in
the 150 mg, 300 mg and placebo groups, respectively. Baseline
characteristics were comparable across groups. At Week 16, mean
change from baseline for overall MASES and at AxS was greater for
secukinumab 150 mg (2.4, 2.3) and 300 mg (2.9, 2.9) vs placebo
(1.9, 1.8; P<0.05, P<0.01). At Week 16, patients treated with
secukinumab 150 mg (40.8%, 42.7%) and 300 mg (36.2%, 42.1%) vs
placebo (28.9%, 30.1%) achieved CR of enthesitis at overall MASES
and AxS. Secukinumab 150 mg and 300 mg were consistently
associated with a higher mean change in MASES and CR of enthesitis
at PS and AT vs placebo. More patients treated with secukinumab
150/300 mg vs placebo achieved a higher threshold of improvement
(5 counts) in overall MASES at Week 16. Further improvements were
observed for all endpoints at Week 52 (Table 1).
Conclusion: Secukinumab 150 mg and 300 mg were associated with a
higher mean change in MASES and CR of enthesitis for overall MASES
and at AxS vs placebo in AS patients at Week 16, which further
improved
TABLE 1:
Week 16 Week 52 Week 16 Week 52 Week 16
LS mean change from baseline in MASES scoreb
Overall MASESd 2.4z 3.5 2.9x 3.9 1.9
AxSe 2.3z 3.2 2.9x 3.6 1.8
PSf 1.3 1.9 1.6 2.1 1.2
ATg 1.0 1.2 1.0 1.3 0.8
Complete resolution of enthesitis (MASES¼0)c, %
Overall MASESd 40.8x 56.4 36.2 52.9 28.9
AxSe 42.7x 58.6 42.1 60.0 30.1
PSf 46.3 65.5 52.5 69.7 38.3
ATg 57.0 78.4 55.0 77.8 48.0
Improvement from baseline in MASES score (5 counts)c, %
Overall MASESd 23.7 34.1 27.6 43.1 16.1
AxSe 20.1 28.0 22.8 32.0 15.4
xP< 0.01; zP< 0.05 vs placebo. aObserved data. bP values from repeated mixed-
effects model until Week 16. cP values from logistic regression model.
Secukinumab 150 mg (n¼ d355, e344, f229, g128); 300 mg (n¼ d58, e57, f40, g20)
and placebo (n¼ d280, e272, f188, g98). AT, Achilles tendons; AxS, MASES minus
AT; LS, least squares; N, number of patients analysed; n, number of patients with
measurement; PS, AT þ lateral condyles of humerus/femur.
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Consultancies; AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim,
Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion,
Pfizer, Regeneron, Roche, UCB. Member of speakers’ bureau; AbbVie,
Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly,
Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron,
Roche, UCB. Grants/research support; AbbVie, Celgene, Centocor,
Merck, Novartis. S. Agawane: Other; Employee of: Novartis. A. Das
Gupta: Other; Employee of: Novartis. S. Mpofu: Other; Employee of:
Novartis. T. Fox: Other; Employee of: Novartis. A. Winseck: Other;
Employee of: Novartis. A. Shete: Shareholder/stock ownership;
Novartis. Other; Employee of: Novartis. B. Porter: Shareholder/stock
ownership; Novartis. Other; Employee of: Novartis.
ii144 EPOSTERS
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/article-abstract/59/Supplem
ent_2/keaa109.035/5822464 by guest on 05 M
ay 2020
